Letairis (Ambrisentan) for Pulmonary Hypertension | myPHteam

Connect with others who understand.

sign up Log in
About myPHteam
Powered By

Letairis is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to improve exercise capacity and limit disease progression in cases of pulmonary arterial hypertension (PAH). Letairis is often prescribed with Adcirca (tadalafil). Letairis may be referred to by its drug name, ambrisentan.

Letairis is an endothelin receptor antagonist. Endothelin is a substance made by the body that causes the blood vessels to constrict. Endothelin receptor antagonists are believed to work by limiting the amount of endothelin in the blood. In cases of PAH, endothelin receptor antagonists may slow disease progression and potentially reverse some heart and lung damage caused by the disease.

How do I take it?
Prescribing information states that Letairis is taken orally once daily. Due to its ability to cause severe birth defects, Letairis is only available to female consumers through a limited distribution program called Letairis Risk Evaluation and Mitigation Strategies (REMS) Program.

Letairis comes in tablet form.

Side effects
The FDA-approved label for Letairis lists common side effects including nasal congestion, sinus infections, flushed skin, and edema (swelling) in the extremities. When used with Adcirca (tadalafil), common side effects of Letairis can also include headache, cough, stomach upset, bronchitis, and anemia.

Rare but serious side effects listed for Letairis include severe birth defects, severe fluid retention, pulmonary edema (fluid in the lungs), blood disorders, and decreased sperm count.

For more details about this treatment, visit:

Letairis — Gilead

Endothelin receptor antagonists — Pulmonary Hypertension Association UK

Continue with Facebook
Continue with Google
Lock Icon Your privacy is our priority. By continuing, you accept our Terms of use, and our Health Data and Privacy policies.
Already a Member? Log in